路平, 魏少忠, 梁新军. 补体系统与肿瘤免疫的研究进展[J]. 中国肿瘤临床, 2021, 48(13): 681-685. DOI: 10.3969/j.issn.1000-8179.2021.13.256
引用本文: 路平, 魏少忠, 梁新军. 补体系统与肿瘤免疫的研究进展[J]. 中国肿瘤临床, 2021, 48(13): 681-685. DOI: 10.3969/j.issn.1000-8179.2021.13.256
Ping Lu, Shaozhong Wei, Xinjun Liang. Advances in research on the relationship between the complement system and antitumor immune response[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(13): 681-685. DOI: 10.3969/j.issn.1000-8179.2021.13.256
Citation: Ping Lu, Shaozhong Wei, Xinjun Liang. Advances in research on the relationship between the complement system and antitumor immune response[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(13): 681-685. DOI: 10.3969/j.issn.1000-8179.2021.13.256

补体系统与肿瘤免疫的研究进展

Advances in research on the relationship between the complement system and antitumor immune response

  • 摘要: 补体系统是先天免疫反应的重要组成部分,但其生物学意义远远超出了简单的非特异性防御。在肿瘤微环境中,补体系统对肿瘤的发生、发展起着双重调控作用,影响免疫应答的结果。通过对免疫系统的调节以及对肿瘤细胞的直接杀伤作用,补体促进了免疫监视并抑制肿瘤进展;然而,过度激活的补体可以通过多种途径影响宿主免疫反应,是炎症、免疫抑制和肿瘤进展之间的重要环节。在抗肿瘤免疫治疗过程中靶向补体系统有助于克服免疫抑制,产生抗肿瘤免疫反应。本文对补体系统与肿瘤免疫的研究进展进行综述,旨在为抗肿瘤免疫治疗提供选择。

     

    Abstract: As an important component of the innate immune response, the complement system has biological significance that goes far beyond simple, non-specific, defense mechanisms. In the tumor microenvironment, the complement system plays a dual role in the occurrence and development of tumors, affecting the outcome of the immune response. Through the regulation of immunity and direct killing of tumor cells, the complement system promotes immune surveillance and inhibits tumor progression; however, an over-activated complement system can affect the immunity of the host, which is an important link among inflammation, immunosuppression, and tumor progression. Targeting to complement contributes to overcoming immunosuppression and leads to an antitumor immune response. This article reviews the recent advances in research on the relationship between the complement system and antitumor immune response with the aim of providing choices for antitumor immunotherapy.

     

/

返回文章
返回